Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiao'er Reping Granules is a Traditional Chinese Medicine (TCM) developed by Jiuhua Huayuan Pharmaceutical Co., Ltd. specifically for pediatric use. It is primarily indicated for the treatment of acute upper respiratory tract infections (AURI) characterized by symptoms such as fever, headache, cough, and sore throat. The formulation is designed to clear internal heat, detoxify the body, and relieve exterior symptoms associated with wind-heat patterns. It contains a complex mixture of herbal ingredients, including *Gypsum Fibrosum*, *Radix Scutellariae*, and *Radix Bupleuri*, which collectively provide antipyretic and anti-inflammatory effects. The drug is administered orally as granules and is widely utilized in the Chinese pediatric market for managing common cold and flu-like illnesses in children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xiao'er reping granules.